Analysis of contribution of xanthine oxidoreductase on the onset and progression of vascular complications in patients with type 2 diabetes.

Analysis of contribution of xanthine oxidoreductase on the onset and progression of vascular complications in patients with type 2 diabetes. - Analysis of contribution of XOR on the onset and progression of vascular complications in patients with type 2 diabetes.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000029257

Enrollment

100

Registered

2017-09-23

Start date

2017-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients with type 2 diabetes (T2DM) 2)18 years or older 3)Male or female 4)Patients without liver dysfunction 5)All subjects must be provided written informed consent prior to entry.

Exclusion criteria

Exclusion criteria: 1)Non-T2DM patients 2)Pregnant, breastfeeding, or patients with no contraception 3)Patients currently taking XOR inhibitors 4)Patients who are inappropriate to enter the trial with any safety reasons, judged by the primary doctors.

Design outcomes

Primary

Measure	Time frame
Plasma xanthine oxidoreductase activities	—

Countries

Japan

Contacts

Public ContactMidori Fujishiro

Nihon University Hospital Department of Internal Medicine

fujishiro.midori@nihon-u.ac.jp03-3293-1711

Outcome results